Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

Affiliations

• ¹ Winship Cancer Institute, Emory University, Atlanta, GA, USA. anooka@emory.edu.
• ² Winship Cancer Institute, Emory University, Atlanta, GA, USA.
• ³ Wake Forest University School of Medicine, Winston-Salem, NC, USA.
• ⁴ University of Chicago Medical Center, Chicago, IL, USA.
• ⁵ OhioHealth, Columbus, OH, USA.
• ⁶ University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.
• ⁷ Cancer & Aging Research Group, St. Louis, MO, USA.
• ⁸ Division of Oncology & Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
• ⁹ Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
• ¹⁰ Greenbaum Cancer Center, University of Maryland, Baltimore, MD, USA.
• ¹¹ Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
• ¹² Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA.
• ¹³ Janssen Research & Development, LLC, Titusville, NJ, USA.
• ¹⁴ Janssen Scientific Affairs, LLC, Horsham, PA, USA.
• ¹⁵ Janssen Research & Development, LLC, Raritan, NJ, USA.
• ¹⁶ Janssen Research & Development, LLC, Leiden, the Netherlands.
• ¹⁷ Dana-Farber Cancer Institute, Boston, MA, USA.
• ¹⁸ Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.